Royalty Report: Drugs, Disease, Cancer – Collection: 248957

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 7

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 7

Primary Industries

  • Drugs
  • Disease
  • Cancer
  • Therapeutic
  • Genome

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 248957

License Grant
Licensor grants to Licensee an exclusive (except as to Licensor) license under the Licensor Patents to the extent necessary to conduct research and development of, and to make, have made, use, offer for sale, sell, have sold and import Licensed Products in the Shared Territory during the term of this Agreement.

Licensor hereby grants Licensee a paid-up non-exclusive license to use Licensor Know-How in the Shared Territory to the extent necessary to research, develop and Commercialize the Licensed Products during the Research Term and while Licensee is co-promoting the applicable Licensed Product in the Shared Territory.

License Property
ONYX-015 means any and all formulations of the genetically engineered adenovirus DL1520 described in US Patent Numbers 5,677,178 and 5,846,945 that selectively replicates in and kills cancer cells based on abnormal p53 pathway function and is currently in clinical trials sponsored by Licensee.

5,677,178 – Cytopathic viruses for therapy and prophylaxis of neoplasia
5,846,945 – Cytopathic viruses for therapy and prophylaxis of neoplasia

Neoplasia is the formation or presence of a new, abnormal growth of tissue.

Gene Product means the adenovirus product selected by Licensor.  The parties collaborate to identify a Gene Product based on incorporation of a specific gene, selected by Licensor and encoding a specific member of one of three classes of proteins, into ONYX-015, or another adenovirus agreed to by the Parties that selectively replicates in and kills cancer cells based on abnormal p53 pathway function, for the purpose of expressing in cancer cells a particular protein with useful anti-cancer activity.

Independent Product shall have the meaning If, Licensor either (A) is not deemed to be diligent(b) or (c) or terminates Development as to a Licensed Product, in each case after the filing of an IND therefor and prior to the End of Phase II Clinical Trials for such Licensed Product, or (B) fails to fulfill its obligations with respect to diligent Development of a Licensed Product after the End of Phase II Clinical Trials.

Pro-Drug Product means the adenovirus product selected by Licensor to identify a Pro-Drug Product based on incorporation of a gene for a prodrug activating enzyme into ONYX-015, or another adenovirus agreed to by the Parties that selectively replicates in and kills cancer cells based on abnormal p53 pathway function, for the purpose of activating a prodrug into a specific active drug form.

Licensed Product means Local/Regional ONYX-015, Systemic ONYX-015, the Pro-Drug Product (upon selection of the Selected Drug System pursuant to this agreement(b)) or the Gene Product (upon selection of the Selected Gene pursuant to this agreement(c)), but excluding those of the foregoing that become Independent Products unless and until such time as Licensor exercises its buy-back rights under this agreement or that become Terminated Products.

Licensor Patent means a Patent that (a) is Controlled by Licensor, and (b) claims the composition of matter, manufacture, and/or use of a Licensed Product, Independent Product or Terminated Product (or any part or aspect of a Licensed Product, Independent Product or Terminated Product), or any aspect of Licensees activities under the Research Program, and including Licensors interest in any Joint Patents.

Local/Regional ONYX-015 means the unmodified ONYX-015 currently in clinical trials sponsored by Licensee, and including any formulation thereof, such as, but without limitation, lyophilized formulations, mouthwash formulations, and formulations that stabilize ONYX-015 for storage at refrigerated or room temperature, but excluding modified formulations that comprise Systemic ONYX-015.

Licensee Patent means a Patent that (A) is Controlled by Licensee, and (B) claims any Invention, or the composition of matter, manufacture, and/or use of ONYX-015 or a Licensed Product (or any part or aspect of a Licensed Product), or any technology necessary to research, develop or commercialize Licensed Products, and including Licensees interest in any Joint Patents.

Invention shall have the meaning that Inventorship of any invention that is developed, discovered or made by a Party or the Parties jointly (as applicable, the Inventor) pursuant to work conducted under this Agreement (an Invention) shall be determined in accordance with United States laws of inventorship.

Field of Use
The rights granted apply to the drug industry.

IPSCIO Record ID: 240474

License Grant
Licensor hereby grants to Licensee a license under the Licensor Patents to the extent necessary to conduct research and development of, and to make, have made, use, offer for sale, sell, have sold and import all Licensed Products throughout the world during the term of this Agreement, which license shall be exclusive (except as to Licensor) in the Shared Territory and shall be exclusive (even as to Licensor) outside of the Shared Territory except that Licensor shall retain such rights in Licensor Patents as shall be necessary to perform its obligations under this Agreement.
License Property
ONYX-015 means any and all formulations of the genetically engineered adenovirus DL1520 described in US Patent Numbers 5,677,178 and 5,846,945 that selectively replicates in and kills cancer cells based on abnormal p53 pathway function and is currently in clinical trials sponsored by Licensor.

Licensor Patent means a Patent that (A) is Controlled by Licensor, and (B) claims any Invention, or the composition of matter, manufacture, and/or use of ONYX-015 or a Licensed Product (or any part or aspect of a Licensed Product), or any technology necessary to research, develop or commercialize Licensed Products, and including Licensors interest in any Joint Patents.

5,801,029 – Cytopathic viruses for therapy and prophylaxis of neoplasia
5,846,945 – Cytopathic viruses for therapy and prophylaxis of neoplasia
5,677,178 – Cytopathic viruses for therapy and prophylaxis of neoplasia

Gene Product means the adenovirus product selected by Licensee. The parties collaborate to identify a Gene Product based on incorporation of a specific gene, selected by Licensee and encoding a specific member of one of three classes of proteins, into ONYX-015, or another adenovirus agreed to by the Parties that selectively replicates in and kills cancer cells based on abnormal p53 pathway function, for the purpose of expressing in cancer cells a particular protein with useful anti-cancer activity.

Independent Product shall have the meaning If, Licensee either (A) is not deemed to be diligent(b) or (c) or terminates Development as to a Licensed Product, in each case after the filing of an IND therefor and prior to the End of Phase II Clinical Trials for such Licensed Product, or (B) fails to fulfill its obligations with respect to diligent Development of a Licensed Product after the End of Phase II Clinical Trials.

Pro-Drug Product means the adenovirus product selected by Licensee to identify a Pro-Drug Product based on incorporation of a gene for a prodrug activating enzyme into ONYX-015, or another adenovirus agreed to by the Parties that selectively replicates in and kills cancer cells based on abnormal p53 pathway function, for the purpose of activating a prodrug into a specific active drug form.

Licensed Product means Local/Regional ONYX-015, Systemic ONYX-015, the Pro-Drug Product (upon selection of the Selected Drug System pursuant to this agreement(b)) or the Gene Product (upon selection of the Selected Gene pursuant to this agreement(c)), but excluding those of the foregoing that become Independent Products unless and until such time as Licensee exercises its buy-back rights under this agreement or that become Terminated Products.

Local/Regional ONYX-015 means the unmodified ONYX-015 currently in clinical trials sponsored by Licensor, and including any formulation thereof, such as, but without limitation, lyophilized formulations, mouthwash formulations, and formulations that stabilize ONYX-015 for storage at refrigerated or room temperature, but excluding modified formulations that comprise Systemic ONYX-015.

Invention shall have the meaning that Inventorship of any invention that is developed, discovered or made by a Party or the Parties jointly (as applicable, the Inventor) pursuant to work conducted under this Agreement (an Invention) shall be determined in accordance with United States laws of inventorship.

Field of Use
ONYX-015 is a novel therapy that uses a genetically modified virus to kill cancer cells.  Onyx-015 is an adenovirus that has been genetically altered so that it only replicates in cells that are lacking a gene called P-53, which is a known tumor suppressor. Because cancer cells lack the gene, the virus multiplies in them and ultimately destroys them. It has no effect on normal cells.

IPSCIO Record ID: 244658

License Grant
The Parties have an acquisition agreement.  Upon consummation of the Acquisition, the Parties desire to establish a new cooperative development program intended to discover, develop, and certify for use in humans one or more new pharmaceutical products.

Licensor grants an exclusive, worldwide license under the Ad Interferon-beta Product Licensor Patents and the Ad Interferon-beta Product Technology to develop, research, make, have made, use, have used, sell, offer for sale, import and have sold the Ad Interferon-beta Product in the Cancer Field and the Beta Interferon Field .

For the Manufacturing License,  Licensor will provide a transferable, limited license or subiicense as the case may be under the Licensor Technology and the Licensor Patents to manufacture such Clinical Vectors and Commercial Vectors to the extent necessary to enable Licensee to manufacture quantities of the Clinical Vectors and Commercial Vectors that otherwise would have been supplied by Licensor to Licensee under this Agreement, solely for use and application by Licensee for the uses and applications in the Territory that would be permitted under this Agreement with respect to such Clinical Vectors and Commercial Vectors purchased from Licensor.

Licensor grants a license, with right to grant sublicenses, under the Licensor Technology and the Licensor Patents to research, develop, manufacture, have manufactured, use, import, export, offer to sell or sell Products in the Territory.

Licensor grants  a nonexclusive, worldwide license, with right to sublicense to Contractors permitted under this Agreement,  to the Licensed Technology, other than the Applied Licensor Technology, as designated in the applicable Project Plan and Budget, and under any Licensor Patents, other than the Exhausted Licensed Patents and the Exempted Licensed Patents, as designated in the applicable Project Plan and Budget, which would, but for this license grant, be infringed by Licensees performance of its Development Tasks solely as necessary for performance of Licensees Development Tasks during and in the course of any approved Development Project.

In addition to the other rights granted under this Agreement, Licensor hereby grants an option to acquire a license, with the right to grant sublicenses, to Licensor Technology, that is not otherwise designated as Applied Licensor Technology in the applicable Project Plan and Budget, and under any and all Targeted Patents, that are not designated as Exhausted Licensor Patents or as Exempted Licensor Patents in the applicable Project Plan and Budget.

License Property
The patents include Adenovirus Vectors for Gene Therapy, and, .Method of Reducing an Immune Response to a Recombinant Adenovirus.

AAV Interferon-beta Product means a Product incorporating the Beta Interferon Gene and any AAV Vector as the delivery platform.

AAV Vector means an adeno-associated viral vector useful or potentially useful for the delivery of Genes to human cells.

Ad Interferon-beta Product means the Product incorporating the Beta Interferon Gene and an Ad Vector that is the subject of the Ad Interferon-beta Project.

Ad Vector means an adenoviral vector useful or potentially useful for the delivery of Genes to human cells.

Field of Use
Beta Interferon Field means the treatment or prevention in humans of one or more diseases through the use or application of one or more gene therapy vectors to deliver Genes; such Genes being defined herein as the Beta Interferon Genes.

Cancer Field means the treatment or prevention in humans of one or more cancers through the use or application of AAV Vectors or Ad Vectors.

IPSCIO Record ID: 291138

License Grant
University hereby grants to Licensee and the Covered Affiliates for the term of this Agreement the worldwide right and license, with the right to grant sublicenses, to develop, have developed, make, have made, use, have used, import, have imported, sell, offer for sale and have sold University Licensed Products under the Group 1 Patents in all fields of use. Such right and license shall be non-exclusive to Licensee.

Group 2 License Grant. University hereby grants to Licensee and the Covered Affiliates for the term of this Agreement the worldwide right and license, with the right to grant sublicenses, to develop, have developed, make, have made, use, have used, import, have imported, sell, offer for sale and have sold University Licensed Products under the Group 2 Patents in all fields of use. Such right and license shall be non-exclusive to Licensee in the LSD Field.  Subject to this Agreement, such right and license shall be exclusive to Licensee outside the LSD Field.

University hereby grants to Licensee and the Covered Affiliates for the term of this Agreement the worldwide right and license, with the right to grant sublicenses, to develop, have developed, make, have made, use, have used, import, have imported, sell, offer for sale and have sold University Licensed Products under the Group 3 Patents in in all fields of use.   Subject to this Agreement, such rights and license shall be exclusive to Licensee.

License Property
Group 1 Patents means the following patents:
US 6,475,769 – Methods and cell line useful for production of recombinant adeno-associated viruses
US 7,238,526 – Methods and cell line useful for production of recombinant adeno-associated viruses

Group 2 Patents means the following patents:
US 6,759,237 – Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US 7,186,552 – Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same

Group 3 Patents means
US 7,056,502 – Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids

University Licensed Product(s) means products that in the absence of this Agreement would, where and when made, used, sold, or imported, infringe at least one issued claim or pending claim of University Patent Rights; and products that are made using a process or machine that in the absence of this Agreement would, where and when used, infringe at least one issued claim or pending claim of University Patent Rights. All University Licensed Products intended to deliver the same Gene shall be considered a single University Licensed Product for purposes of this Agreement.

University Patent Rights means those patents and patent applications listed in this Agreement and all foreign counterparts thereof, as well as continuation, continuation-in-part, provided that such continuation-in-part relates directly to existing patents or patent applications and not to any new matter, divisional and re-issue applications
thereof, together with any and all patents issuing thereupon or upon any foreign counterparts thereof; provided, however, that Licensee acknowledge that the invention relating to non-invasive delivery of transgenes into the bloodstream, which is disclosed in Example 6 of International Patent Application No. PCT/USO1/13000 (M2304PCT), and in a US CIP application No. 09/955,444 (N2605), was made at University following termination of the research under the Sponsored Research Agreement.  Licensee hereby acknowledge that they have no rights in this invention relating to non-invasive delivery of transgenes into the bloodstream, as defined in these applications and divisionals, continuations, re-examinations, re-issues, and any foreign counterparts thereof, and any patents issuing therefrom. Licensee agree that they will not make or pursue any claims that this invention as so defined is or should have been part of the University Patent Rights.

Gene means any nucleotide sequence that is capable of encoding, or of causing or modulating the expression of, a proteiin, protein fragment, or other genetic element.  For the purposes hereof, a Gene having 90% homology to that of another Gene, and which expresses essentially the same protein for at least one biological function, shall be considered the same Gene as such other Gene.

LSD Field means the prevention, treatment, or cure of lysosomal storage diseases whether by in vivo or ex vivo means (together with preparation, research, development, and attempts to do the foregoing).

Cancer Field means the prevention, treatment or cure of malignancies whether by in vivo or ex vivo means together with preparation, research, development, and attempts to do the foregoing).

TNFr/Inflammatory Field means the prevention, treatment, or cure of any disease or diseases in whole or in part through use or delivery of the TNFr Gene or any other Gene acting in the Inflammatory Pathway, whether by in vivo or ex vivo means (together with preparation, research, development, and attempts to do the foregoing).

Field of Use
This agreement pertains to the drug industry relating to Gene Therapy.

IPSCIO Record ID: 215176

License Grant
The Japanese Licensor grants the Licensee a non-exclusive license to practice inventions claimed in or covered by patents and patent applications owned or controlled by such Party relating to the discovery and commercialization of Independent Lead Compounds, Independent Products, Lead Compounds, Collaboration Lead Compounds or Products made or discovered during the Research Program Term, other know-how, information and technology owned or controlled by the other Party and developed during Research Program Term, patents and patent applications owned or controlled by such Party to the extent applicable to the Field existing as of the Agreement Date and know-how, information and technology existing as of the Agreement Date owned or controlled by such Party to the extent applicable to the Field solely for the purpose of conducting the Research Program.

In addition to the cross license, the Japanese Licensor will grant an exclusive, sub-licensable, worldwide license, to make, use and sell compounds, Collaboration Lead Compounds or Products under Licensors interest in Program Patents and Program Know-How and under terms and conditions to be separately agreed, Licensor will also grant a nonexclusive, sub-licensable, worldwide license under any Licensor Patent Rights and Know-How to the extent necessary to practice the license granted under the Program Patents and Program Know-How, including, with respect to compounds, a limited number of Licensors library compounds approved by Licensor.

And Licensor grants an exclusive, except as to Licensor, license, with the right to sublicense under the Program Patents, Program Know-How, Patent Rights and Know-How owned or controlled by Licensor during the Term to the extent necessary to develop, make, have made, use, import, offer for sale and sell any Product in the Co-Promotion Territory; and an exclusive, even as to Licensor, license, with the right to sublicense, under the Program Patents, Program Know-How, Patent Rights and Know-How owned or controlled by Licensor during the Term to the extent necessary to develop, make, have made, use, import, offer for sale and sell, with the right to sublicense, any Product in the Licensees Territory.

License Property
The parties are participating in a collaborative program to research, discover, develop, manufacture and market products that agonize or antagonize Orphan Nuclear Receptors.

An orphan receptor is an apparent receptor that has a similar structure to other identified receptors but whose endogenous ligand has not yet been identified. If a ligand for an orphan receptor is later discovered, the receptor is referred to as an 'adopted orphan'.

Orphan nuclear receptors act as regulatory proteins in a wide variety of biological processes. This, in combination with the fact that nuclear receptors are known to be activated by naturally occurring small molecules, makes orphan nuclear receptors excellent targets for orally active drugs. The goal of the collaboration is to clarify the biology of individual orphan nuclear receptors and to discover small molecules that are capable of regulating the activity of these receptors to cure or control disease.

Independent Products incorporate or are based on such Collaboration Lead Compound.

Field of Use
The field of use is the treatment of disease in humans.

IPSCIO Record ID: 211855

License Grant
Licensor grants the Japanese Licensee a non-exclusive license to practice inventions claimed in or covered by patents and patent applications owned or controlled by such Party relating to the discovery and commercialization of Independent Lead Compounds, Independent Products, Lead Compounds, Collaboration Lead Compounds or Products made or discovered during the Research Program Term, other know-how, information and technology owned or controlled by the other Party and developed during Research Program Term, patents and patent applications owned or controlled by such Party to the extent applicable to the Field existing as of the Agreement Date and know-how, information and technology existing as of the Agreement Date owned or controlled by such Party to the extent applicable to the Field solely for the purpose of conducting the Research Program.

In addition to the cross license, Licensor grants an exclusive, except as to Licensor, license, with the right to sublicense, under the Program Patents, Program Know-How, Patent Rights and Know-How owned or controlled by Licensor during the Term to the extent necessary or useful to develop, make, have made, use, import, offer for sale and sell any Product in the Co-Promotion Territory; and an exclusive, even as to Licensor, license, with the right to sublicense, under the Program Patents, Program Know-How, Patent Rights and Know-How owned or controlled by Licensor to the extent necessary to develop, make, have made, use, import, offer for sale and sell any Product in the Licensees Territory.

And, Licensor grants an exclusive, except as to Licensor, license, under the Program Patents, Program Know-How, Patent Rights and Know-How owned or controlled by Licensor, during the Term to the extent necessary or useful to develop, make, have made, use, import, offer for sale and sell any Product in the Co-Promotion Territory; and an exclusive, even as to Licensor, license, with the right to sublicense, under the Program Patents, Program Know-How, Patent Rights and Know-How owned or controlled by Licensor to the extent necessary to develop, make, have made, use, import, offer for sale and sell any Product in the Licensees Territory.

License Property
The parties are participating in a collaborative program to research, discover, develop, manufacture and market products that agonize or antagonize Orphan Nuclear Receptors.

An orphan receptor is an apparent receptor that has a similar structure to other identified receptors but whose endogenous ligand has not yet been identified. If a ligand for an orphan receptor is later discovered, the receptor is referred to as an 'adopted orphan'.

Orphan nuclear receptors act as regulatory proteins in a wide variety of biological processes. This, in combination with the fact that nuclear receptors are known to be activated by naturally occurring small molecules, makes orphan nuclear receptors excellent targets for orally active drugs. The goal of the collaboration is to clarify the biology of individual orphan nuclear receptors and to discover small molecules that are capable of regulating the activity of these receptors to cure or control disease.

Independent Products incorporate or are based on such Collaboration Lead Compound.

Field of Use
The field of use is the treatment of disease in humans.

IPSCIO Record ID: 256313

License Grant
Licensor grants:
–  a non exclusive license in the Territory under the Licensor Know-How and Patent Rights for the limited purpose of allowing Licensee to conduct the obligations and responsibilities allocated to Licensee under the Research Program, including without limitation, to evaluate Licensees interest in designating a Nominated Compound as a Licensed Compound pursuant to this Agreement.

–  a perpetual, non exclusive license in the Territory under Licensor Patent Rights and Know-How solely for Licensee and its Affiliates internal research purposes for screening compounds against the Target for the sole purpose of identifying compounds that do not modulate and/or bind to the Target.

–  an exclusive license in the Territory, with the right to sublicense under Licensor Patent Rights, Know-How and interest in Joint Information and Inventions and Joint Patent Rights, to develop, use, make, have made, offer to sell, sell or import Licensed Compounds and Products for any and all purposes.

License Property
The Target shall mean STAT3 with Gene entrex ID#6774.

Prerequisites for Proof of Concept for Lead Compounds.
1. Global gene expression of inhibitor is consistent with global gene expression caused by STAT3 RNAi knockout or STAT3 inhibitor peptide in multiple cancer cell line:;

2. Pathway specific differential gene expression activity (the compound has limited off target activity as assessed in cellular systems where STAT 3 is not induced).

3 Stat 3 protein cellular status is altered in on or more of its properties (ie,
phosphorylation state, nuclear localization, DNA binding, and cellular protein levels.

4. The compound inhibition correlate target activity in a dose dependent manner with inhibition of cell proliferation and/or induction of apoptosis in a cellular system when STAT3 is activated. Percentage inhibition is statistically significant (at least 3 standard deviations) in two independent experiments.

5. Demonstrated chemistry tractability as defined below
Apparent Structure Activity Relationship profile (with 10 compounds)
Equal to or over 20 fold selectivity for the STAT3 pathway over STAT1 pathway as measured by IC50, IC70 or IC90 with a P value of at least 0.05. During the Research Program either Party may propose a different level of selectivity or assay format as being more appropriate, but such different level shall apply only if the Parties mutually agree in writing.

Field of Use
The field of use is for Cancer Indications, meaning a separate and distinct disease or medical condition in humans for which a Product that is in Clinical Trials is intended to treat and/or prevent and/or for which a Product has received Marketing Authorization for such treatment and/or prevention for the following disease and medical conditions: the following solid tumor  cancers: non small cell lung cancer, prostate cancer, breast cancer and co!orectal cancer; each a Major Tumor Indication; or any cancer type in humans.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.